Comparison
Lixisenatide vs. Mazdutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
320367-13-3
2259884-03-0
Molecular weight
4858.5 g/mol
4790 g/mol
Half-life
3 h
132 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteMechanism of action
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
5
4
Effects recorded
3
4
Open conflicts
1
0
Documented adverse events
1
0
Legal status
Full entries
Frequently asked questions
- What is the difference between Lixisenatide and Mazdutide?
- Lixisenatide is classified as "Metabolic", while Mazdutide is classified as "Metabolic". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Mazdutide?
- The highest available evidence level is "Human RCT" for Lixisenatide and "Human RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Mazdutide in Germany and the United States?
- Germany: Lixisenatide — Prescription, Mazdutide — Research only. United States: Lixisenatide — Unapproved, Mazdutide — Research only. These are factual summaries with source and review date on the individual pages.